source
- Frazier Life Sciences raises over $1.1 billion for its small-mid-cap biotech fund, total commitments now $2.8 billionFrazier Life Sciences announced that it has added more than $1.1 billion in new capital to its public fund that targets small and mid‑size biopharma companies. The infusion brings the fund's total…
- Solstice Oncology secures $225M Series A to launch FDA-cleared Phase 2 CTLA-4 antibody trialSolstice Oncology, a cancer-focused startup that emerged from stealth in February, announced a $225 million Series A financing round to fund its early-stage programs. The capital will be used to a…